Prognostic Significance of Neutropenia on Day One of Anthracycline-Based Neoadjuvant Chemotherapy in Operable Breast Cancer

被引：5

作者：

Ishitobi, Makoto ^{[1
]}

Komoike, Yoshifumi ^{[1
]}

Motomura, Kazuyoshi ^{[1
]}

Koyama, Hiroki ^{[1
]}

Inaji, Hideo ^{[1
]}

机构：

[1] Osaka Med Ctr Canc & Cardiovasc Dis, Dept Breast & Endocrine Surg, Higashinari Ku, Osaka 5378511, Japan

来源：

ONCOLOGY | 2010年 / 78卷 / 3-4期

关键词：

Breast cancer; Neoadjuvant chemotherapy; Neutropenia; Prognosis; METASTATIC COLORECTAL-CANCER; CELL LUNG-CANCER; ADJUVANT CHEMOTHERAPY; STAGE-II; EFFICACY; TRIAL; CYCLOPHOSPHAMIDE; FLUOROURACIL; EPIRUBICIN; CARCINOMA;

D O I：

10.1159/000313702

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Objectives: It is currently unknown whether neutropenia during neoadjuvant chemotherapy for early breast cancer is associated with prognosis. Methods: We retrospectively analyzed 103 breast cancer patients who were treated with neoadjuvant chemotherapy including epirubicin-based chemotherapy followed by docetaxel. The association between neutropenia due to epirubicin-based chemotherapy and distant disease-free survival (DDFS) was assessed. Results: Thirty-one patients (30%) demonstrated neutropenia during the epirubicin-based regimen. Patients without neutropenia showed a significantly (p = 0.004) lower 5-year DDFS rate (64%) than those with neutropenia (97%). In addition, multivariate analysis showed that neutropenia is an independent prognostic factor for DDFS (p = 0.02). Conclusion: Neutropenia occurring in early breast cancer patients during the initial neoadjuvant treatment is strongly associated with a better prognosis. Copyright (C) 2010 S. Karger AG, Basel

引用

页码：213 / 219

页数：7

共 29 条

[1] Early Changes in Functional Dynamic Magnetic Resonance Imaging Predict for Pathologic Response to Neoadjuvant Chemotherapy in Primary Breast Cancer [J].

Ah-See, Mei-Lin W. ;

Makris, Andreas ;

Taylor, N. Jane ;

Harrison, Mark ;

Richman, Paul I. ;

Burcombe, Russell J. ;

Stirling, J. James ;

d'Arcy, James A. ;

Collins, David J. ;

Pittam, Michael R. ;

Ravichandran, Duraisamy ;

Padhani, Anwar R. .

CLINICAL CANCER RESEARCH, 2008, 14 (20) :6580-6589

[2] Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer:: a randomised trial [J].

Bergh, J ;

Wiklund, T ;

Erikstein, B ;

Lidbrink, E ;

Lindman, H ;

Malmström, P ;

Kellokumpu-Lehtinen, P ;

Bengtsson, NO ;

Söderlund, G ;

Anker, G ;

Wist, E ;

Ottosson, S ;

Salminen, E ;

Ljungman, P ;

Holte, H ;

Nilsson, J ;

Blomqvist, C ;

Wilking, N .

LANCET, 2000, 356 (9239) :1384-1391

[3] DOSE-RESPONSE EFFECT OF ADJUVANT CHEMOTHERAPY IN BREAST-CANCER [J].

BONADONNA, G ;

VALAGUSSA, P .

NEW ENGLAND JOURNAL OF MEDICINE, 1981, 304 (01) :10-15

[4] Moderate neutropenia with adjuvant CMF confers improved survival in early breast cancer [J].

Cameron, DA ;

Massie, C ;

Kerr, G ;

Leonard, RCF .

BRITISH JOURNAL OF CANCER, 2003, 89 (10) :1837-1842

[5] MRI evaluation of pathologically complete response and residual tumors in breast cancer after neoadjuvant chemotherapy [J].

Chen, Jeon Hor ;

Feig, Lyon ;

Agrawal, Garima ;

Yu, Hon ;

Carpenter, Philip M. ;

Mehta, Rita S. ;

Nalcioglu, Orhan ;

Su, Min Ying .

CANCER, 2008, 112 (01) :17-26

[6] Role of epidermal growth factor receptor pathway-targeted therapy in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck [J].

Cohen, Ezra E. W. .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (17) :2659-2665

[7] Chemotherapy-induced neutropenia - Risks, consequences, and new directions for its management [J].

Crawford, J ;

Dale, DC ;

Lyman, GH .

CANCER, 2004, 100 (02) :228-237

[8] A prospective pharmacologic evaluation of age-related toxicity of adjuvant chemotherapy in women with breast cancer [J].

Dees, EC ;

O'Reilly, S ;

Goodman, SN ;

Sartorius, S ;

Levine, MA ;

Jones, RJ ;

Grochow, LB ;

Donehower, RC ;

Fetting, JH .

CANCER INVESTIGATION, 2000, 18 (06) :521-529

[9] Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of three randomised trials [J].

Di Maio, M ;

Gridelli, C ;

Gallo, C ;

Shepherd, F ;

Piantedosi, FV ;

Cigolari, S ;

Manzione, L ;

Illiano, A ;

Barbera, S ;

Robbiati, SF ;

Frontini, L ;

Piazza, E ;

Ianniello, GP ;

Veltri, E ;

Castiglione, F ;

Rosetti, F ;

Gebbia, V ;

Seymour, L ;

Chiodini, P ;

Perrone, F .

LANCET ONCOLOGY, 2005, 6 (09) :669-677

[10]

Ferguson T, 2007, COCHRANE DB SYST REV, V17

← 1 2 3 →